Vulvar vestibulitis syndrome and estrogen dose of oral contraceptive pills

J Sex Med. 2007 Nov;4(6):1679-83. doi: 10.1111/j.1743-6109.2007.00621.x.

Abstract

Introduction: Vulvar vestibulitis syndrome (VVS) is a diverse, multifactorial phenomenon. Its precise etiology is unknown.

Aim: To define the association between oral contraceptive (OC) estrogen dosage and VVS. Methods. Women diagnosed as having VVS participated in the study.

Main outcome measures: Data on type and usage of oral contraceptive pills (OC) were obtained by a questionnaire, and they were compared for the data on OC usage in the general population.

Results: Available commercial data on Israeli women taking OC showed that 51% of them use low-dose estrogen (</=20 microg) OC and 49% use higher-dose estrogen (30-35 microg) OC. Of the 132 women in the study, 86 (65%) used OC: 68 (79%) used low-dose estrogen OC (P < 0.002 compared to the general population), while only 18 (21%) used high-dose estrogen OC (P < 0.002 compared to the general population).

Conclusion: Significantly more patients who are treated in our clinic for VVS use low-dose estrogen than those who use high-dose estrogen OC.

MeSH terms

  • Adult
  • Contraception Behavior / statistics & numerical data
  • Contraceptives, Oral, Hormonal / administration & dosage
  • Contraceptives, Oral, Hormonal / adverse effects*
  • Dose-Response Relationship, Drug
  • Estrogens / administration & dosage
  • Estrogens / adverse effects*
  • Female
  • Humans
  • Israel / epidemiology
  • Vulvar Vestibulitis / chemically induced
  • Vulvar Vestibulitis / diagnosis*
  • Vulvar Vestibulitis / epidemiology*
  • Women's Health*

Substances

  • Contraceptives, Oral, Hormonal
  • Estrogens